Volume Spike Investor

Human Genome Sciences Inc. (HGSI) gave positive data on its Lupus studies.  This showed that Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy.  In early trading at 7:59 AM EST shares up 15% or so pre-market from $2.71 close to $3.15 in early trading on about 25,000 shares… Its 52-week range is $0.45 to $8.00 and average volume is 3 million shares.  -Jon Ogg